The new Start dressing range--Urgotul Start, UrgoCell Start.
Delayed wound healing has implications both for the clinician and the patient, as well as having a financial burden on the National Health Service. UrgoCell Start and Urgotul Start are the first dressings on the drug tariff to be impregnated with Nano-OligoSaccharide Factor (NOSF), a new compound that aims to promote wound closure through the inhibition of matrix metalloproteinase (MMP) activity. The dressings are designed to 'kick-start' wounds that are at risk of delayed healing. there is good clinical evidence, comprising multi-centre Randomized Controlled Trials, an observational study and case studies, to support the process of MMP inhibition and its clinical efficacy in kick-starting wound healing.